Quick Answer
BridgeBio Pharma, Inc. reported Research And Development Expense of $451.95 million for the year ending 2025.
- BridgeBio Pharma, Inc. showed a decrease of -10.8% in Research And Development Expense from 2024 to 2025.
- This data is from BridgeBio Pharma, Inc.'s annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2018: $31.15 million | Q1 2019: $44.85 million | Q2 2019: $52.33 million | Q3 2019: $55.28 million | Q1 2020: $68.23 million | Q2 2020: $86.60 million | Q3 2020: $92.05 million | Q1 2021: $122.56 million | Q2 2021: $101.96 million | Q3 2021: $104.31 million | Q1 2022: $107.65 million | Q2 2022: $108.40 million | Q3 2022: $92.51 million | Q1 2023: $92.86 million | Q2 2023: $107.49 million | Q3 2023: $125.14 million | Q1 2024: $140.97 million | Q2 2024: $114.70 million | Q3 2024: $120.44 million | Q1 2025: $111.43 million | Q2 2025: $111.23 million | Q3 2025: $112.87 million.
- Over the full 9 years of available data (2017 to 2025), BridgeBio Pharma, Inc.'s Research And Development Expense has grown by 1,379.1%.
- Historical annual values: Fiscal year 2025: $451.95 million | Fiscal year 2024: $506.46 million | Fiscal year 2023: $455.71 million | Fiscal year 2022: $399.46 million | Fiscal year 2021: $451.02 million | Fiscal year 2020: $337.05 million | Fiscal year 2019: $209.95 million | Fiscal year 2018: $140.07 million | Fiscal year 2017: $30.56 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: